Zobrazeno 1 - 10
of 30
pro vyhledávání: '"Eiichi Fuse"'
Autor:
Eiichi Fuse, Jun Hosogi, Hiroshi Maeda, Takashi Kuwabara, Rui Ohashi, Yorihiro Yamamoto, Satoshi Tashiro
Publikováno v:
Drug metabolism and pharmacokinetics. 32(5)
(E)-1-{4-[2-(1H-Indazol-3-yl)vinyl]benzoyl}piperazine (KW-2449) is a novel multikinase inhibitor. During our clinical study, we found that KW-2449 is mainly metabolized to its oxo-piperazine form (M1). An inhibition study suggested that monoamine oxi
Publikováno v:
Drug Metabolism and Disposition. 42:983-989
A pharmacokinetic model was constructed to explain the difference in brain- and cerebrospinal fluid (CSF)-to-plasma and brain-to-CSF unbound drug concentration ratios (Kp,uu,brain, Kp,uu,CSF, and Kp,uu,CSF/brain, respectively) of drugs under steady-s
Publikováno v:
Drug Metabolism and Pharmacokinetics. 23:106-114
Olopatadine, a new second-generation antihistamine, is widely used in the treatment of allergic disorders. The low levels of histamine H1 receptor occupancy in human brain by olopatadine, which is related to its minimal sedation, suggest its low pene
Publikováno v:
The Journal of Clinical Pharmacology. 45:394-403
UCN-01 is a protein kinase inhibitor under development as a novel anticancer drug. The initial pharmacologic features in patients were not predicted from preclinical experiments. The distribution volume and the systemic clearance were much lower than
Autor:
Etsuo Ohshima, Hiromasa Miyaji, Hideki Mimura, Toshihide Ikemura, Akira Karasawa, Haruhiko Manabe, Masatsugu Sawada, Eiichi Fuse, Kimihisa Ueno, Osamu Kotera, Satoshi Tashiro
Publikováno v:
Journal of Pharmacology and Experimental Therapeutics. 314:244-251
Prostaglandin (PG) D2, a major cyclooxygenase metabolite generated from immunologically stimulated mast cells, is known to induce activation and chemotaxis in eosinophils, basophils, and T helper 2 (Th2) lymphocytes via a newly identified PGD2 recept
Autor:
Hiroyoshi Nishiie, Hiroyuki Kobayashi, Takashi Kuwabara, Takayoshi Oishi, Tomoko Kuramitu, Noriaki Kurata, Satoshi Kobayashi, Eiichi Fuse, Kenichi Yasoshima
Publikováno v:
Cancer Chemotherapy and Pharmacology. 47:106-112
Purpose: To evaluate the metabolic fate of UCN-01, a signal transduction inhibitor, blood and plasma concentrations, distribution, metabolism and excretion were investigated in rats and dogs after intravenous administration of [3H]UCN-01. Methods: Th
Autor:
Hiromi Tanii, Natsuko Sato, Satoshi Kobayashi, Eiichi Fuse, Akitoshi Hashimoto, Takashi Kuwabara, Yuichi Sugiyama
Publikováno v:
Pharmaceutical Research. 17:553-564
Purpose. The extremely low clearance and small distribution volumeof UCN-01 in humans could be partly due to the high degree of bindingto hAGP (1,2). The quantitative effects of hAGP on the pharmacokineticsof UCN-01 at several levels of hAGP and UCN-
Autor:
Kazuo Yamaguchi, Michio Takashima, Eiichi Fuse, Takashi Kuwabara, Tohru Yasuzawa, Satoshi Kobayashi
Publikováno v:
Journal of Chromatography B: Biomedical Sciences and Applications. 713:447-451
A sensitive method for the determination of an anti-cancer agent, DX-52-1 (7-cyanoquinocarcinol, I) and quinocarmycin (II) which is formed from I either by metabolism or degradation, in human plasma has been developed utilising liquid chromatography
Autor:
Richard D. Lush, Eiichi Fuse, Hiromi Tanii, Adrian M. Senderowicz, Donna Headlee, Satoshi Kobayashi, Adaline C. Smith, William D. Figg, Susan G. Arbuck, Takashi Kuwabara, Edward A. Sausville
Publikováno v:
Cancer Chemotherapy and Pharmacology. 42:S54-S59
UCN-01 (7-hydroxystaurosporine; NSC 638850) is a protein kinase antagonist selected for clinical trial based in part on evidence of efficacy in a preclinical renal carcinoma xenograft model. Schedule studies and in vitro studies suggested that a 72-h
Autor:
Hiromitsu Saito, Masaji Kasai, Uichiro Kimura, Eiichi Fuse, Nobuyuki Yoda, Hiroyuki Ishida, Katsushige Gomi, Tsutomu Akama, Y. Shida, Satoshi Kobayashi
Publikováno v:
Journal of Medicinal Chemistry. 40:1894-1900
Recently, we reported that 5,4'-diaminoflavone (1) exhibits potent and specific growth-inhibitory activity against the estrogen receptor (ER)-positive human breast cancer cell line MCF-7. However, when compound 1 was incubated with S-9 mix, its metab